Why LIB Therapeutics’ lerodalcibep data matter for next-generation cholesterol care
Monthly PCSK9 therapy is getting crowded. LIB Therapeutics’ LEROCHOL data raise a sharper question on adherence, access and durability.
Pharma & Biotech
Pharma & Biotech
Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.